Home › Lung Cancer › Connecticut › Stamford
Lung Cancer clinical trials in Stamford, CT
10 studies for Lung Cancer are looking for participants at sites in and around Stamford (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich · 5 mi away
- Good Samaritan University Hospital, West Islip · 27 mi away
- Northwell Health Imbert Cancer Center, Bay Shore · 27 mi away
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
RecruitingPhase 3
- Stamford Hospital/Bennett Cancer Center, Stamford
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RecruitingPhase 3
- Smilow Cancer Hospital Care Center at Long Ridge, Stamford
- Stamford Hospital/Bennett Cancer Center, Stamford
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich · 5 mi away
- and 1 more
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RecruitingPhase 3
- Stamford Hospital ( Site 0083), Stamford
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
RecruitingPhase 3
- Northwell Health Cancer Institute at Huntington, Greenlawn · 16 mi away
- Northwell Health Imbert Cancer Center, Bay Shore · 27 mi away
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- Smilow Cancer Hospital Care Center at Long Ridge, Stamford
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich · 5 mi away
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- Smilow Cancer Hospital Care Center at Long Ridge, Stamford
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich · 5 mi away
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Smilow Cancer Hospital Care Center at Long Ridge, Stamford
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich · 5 mi away
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
RecruitingObservational study
- Stamford Hospital, Stamford
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
RecruitingObservational study
- The Stamford Health/The Stamford Hospital, Stamford
- Good Samaritan Cancer Center, West Islip · 27 mi away
About Lung Cancer
Lung cancer forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.
More about Lung Cancer on MedlinePlus
Lung Cancer trials in other cities
- Houston, TX78 studies
- Boston, MA62 studies
- New York City, NY60 studies
- Los Angeles, CA45 studies
- Washington, DC41 studies
- Chicago, IL41 studies
- Arlington, VA40 studies
- Nashville, TN40 studies
- Baltimore, MD40 studies
- St. Louis, MO39 studies
- Columbus, OH36 studies
- Philadelphia, PA36 studies
Other studies in Stamford
- Breast Cancer9 studies
- Non-Small Cell Lung Cancer8 studies
- Obesity6 studies
- Migraine6 studies
- Prostate Cancer5 studies
- Ovarian Cancer5 studies
- Cardiovascular Disease4 studies
- Pancreatic Cancer4 studies
- Overweight4 studies
- Neurologic Diseases3 studies
- Cancer (all types)3 studies
- Heart Failure3 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.